The appearance of antibodies (Abs) against the drug has been described in about half of the patients receiving repeated TNFα monotherapy; as a consequence, immune suppression by concomitant administration of methotrexate (MTX) is recommended both in RA and SpA patients [10–18]. The gene discussed is TNF; the disease is rheumatoid arthritis.